Protective Effect of Naturally Acquired Homotypic and Heterotypic Rotavirus Antibodies

Chiba, Shunzo; Nakata, Shuji; Urasawa, Tomoko; Urasawa, Shozo; Yokoyama, Takashi; Morita, Yasuyuki; Taniguchi, Koki; Nakao, Tooru

doi:10.1016/s0140-6736(86)92133-1

Cited by 243 publications

(117 citation statements)

References 16 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…50 In contrast, the association between serum homotypic or heterotypic NA was not detected in another study of adults experimentally infected with a different RV. 46 A relationship between serum RV-NA and protection against natural infection has been observed in children attending an orphanage 51 or a daycare center, 52 and in a case-control study in rural Bangladesh. 53 Nonetheless, this relationship has not been observed in another community study.…”

Section: Correlates Of Protection After Rv Natural and Experimental Imentioning

confidence: 99%

Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges

Ángel

Steele

Franco

2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Rotavirus (RV) is a major vaccine-preventable killer of young children worldwide. Two RV vaccines are globally commercially available and other vaccines are in different stages of development. Due to the absence of a suitable correlate of protection (CoP), all RV vaccine efficacy trials have had clinical endpoints. These trials represent an important challenge since RV vaccines have to be introduced in many different settings, placebo-controlled studies are unethical due to the availability of licensed vaccines, and comparator assessments for new vaccines with clinical endpoints are very large, complex, and expensive to conduct. A CoP as a surrogate endpoint would allow predictions of vaccine efficacy for new RV vaccines and enable a regulatory pathway, contributing to the more rapid development of new RV vaccines. The goal of this review is to summarize experiences from RV natural infection and vaccine studies to evaluate potential CoP for use as surrogate endpoints for assessment of new RV vaccines, and to explore challenges and opportunities in the field.

show abstract

Section: Correlates Of Protection After Rv Natural and Experimental Imentioning

confidence: 99%

Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges

Ángel

Steele

Franco

2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Because natural rotavirus infections provide protection against subsequent rotavirus disease, particularly against severe disease, vaccines evaluated in clinical trials to date have all been comprised of live, attenuated rotavirus strains that are delivered orally to mimic natural infection. Protection after natural rotavirus infection has been associated with both serum and intestinal rotavirus antibodies (11,18,19,41,65,68). Even though similar associations have been difficult to establish after live virus immunization (69), very recent evidence suggests a strong correlation between the presence of serum rotavirus IgA and protection following immunization with Rotarix, a candidate vaccine that was licensed in Mexico in 2004 (20).…”

mentioning

confidence: 99%

Mice Develop Effective but Delayed Protective Immune Responses When Immunized as Neonates either Intranasally with Nonliving VP6/LT(R192G) or Orally with Live Rhesus Rotavirus Vaccine Candidates

VanCott

Prada

McNeal

et al. 2006

J Virol

View full text Add to dashboard Cite

Rotavirus vaccines are delivered early in life, when the immune system is immature. To determine the effects of immaturity on responses to candidate vaccines, neonatal (7 days old) and adult mice were immunized with single doses of either Escherichia coli-expressed rotavirus VP6 protein and the adjuvant LT(R192G) or live rhesus rotavirus (RRV), and protection against fecal rotavirus shedding following challenge with the murine rotavirus strain EDIM was determined. Neonatal mice immunized intranasally with VP6/LT(R192G) were unprotected at 10 days postimmunization (dpi) and had no detectable rotavirus B-cell (antibody) or CD4

show abstract

“…Serum-neutralizing antibodies, as correlates of protection, are also under debate. Several studies have shown that preexisting homotypic neutralizing antibodies in children correlate with protection from rotavirus infection and disease (5,6,14,29,30), whereas Ward et al (40) found some correlation only with heterotypic neutralizing antibodies.…”

mentioning

confidence: 99%

Memory T-Cell Response to Rotavirus Detected with a Gamma Interferon Enzyme-Linked Immunospot Assay

Kaufhold¹,

Field²,

Caulfield³

et al. 2005

J Virol

View full text Add to dashboard Cite

show abstract

Protective Effect of Naturally Acquired Homotypic and Heterotypic Rotavirus Antibodies

Cited by 243 publications

References 16 publications

Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges

Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges

Mice Develop Effective but Delayed Protective Immune Responses When Immunized as Neonates either Intranasally with Nonliving VP6/LT(R192G) or Orally with Live Rhesus Rotavirus Vaccine Candidates

Memory T-Cell Response to Rotavirus Detected with a Gamma Interferon Enzyme-Linked Immunospot Assay

Contact Info

Product

Resources

About